Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.

Rahma, O E; Duffy, A; Liewehr, D J; Steinberg, S M; Greten, T F

Rahma, O E; Duffy, A; Liewehr, D J; Steinberg, S M; Greten, T F.

Affiliation

Rahma OE; Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Ann Oncol ; 24(8): 1972-9, 2013 Aug.

Article in En | MEDLINE | ID: mdl-23670093

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Pancreatic Neoplasms/drug therapy; Antimetabolites, Antineoplastic/therapeutic use; Bridged-Ring Compounds/therapeutic use; Deoxycytidine/analogs & derivatives; Deoxycytidine/therapeutic use; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil/therapeutic use; Humans; Pancreatic Neoplasms/mortality; Platinum Compounds/therapeutic use; Protein Kinase Inhibitors/therapeutic use; Quinazolines/therapeutic use; Survival; Taxoids/therapeutic use; Gemcitabine

Key words

analysis; cancer; pancreatic; review; second-line; treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2013 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google